MRNA - Moderna, Inc.

54.23
-0.360   -0.664%

Share volume: 5,948,015
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$54.59
-0.36
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
13%
Profitability 0%
Dept financing 9%
Liquidity 45%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.95%
1 Month
5.75%
3 Months
4.55%
6 Months
101.97%
1 Year
110.68%
2 Year
-48.09%
Key data
Stock price
$54.23
P/E Ratio 
0.00
DAY RANGE
$51.68 - $56.20
EPS 
-$7.26
52 WEEK RANGE
$22.28 - $59.55
52 WEEK CHANGE
$104.33
MARKET CAP 
11.521 B
YIELD 
N/A
SHARES OUTSTANDING 
394.939 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
0.33
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$6,729,894
AVERAGE 30 VOLUME 
$5,822,970
Company detail
CEO: Stéphane Bancel
Region: US
Website: modernatx.com
Employees: 3,900
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Moderna, Inc. develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. The company has 44 development programs, which includes 26 in clinical trials across seven modalities.

Recent news